denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Lymphoid Leukemias, ALL, Diseases, Lymphoid Malignancies
Description:
The treatment of acute lymphoblastic leukemia (ALL) is changing rapidly with the application of intensive pediatric regimens for adolescents and young adults, improved risk stratification with sensitive techniques for detection of measurable residual disease, and the application of novel, highly-active targeted therapies for Ph-negative and Ph-positive B-cell ALL. The purpose of this session is to understand current treatment approaches and ongoing clinical trials intended to improve cure rates and survival while reducing toxicity for older patients.
Nicolas Boissel, MD, PhD will discuss current approaches and ongoing clinical trials integrating novel agents for adolescents and young adults with ALL.
Kristen O'Dwyer, MD will provide an update of the treatment of T-cell ALL and future directions in the treatment of this rare disease.
Matthew Wieduwilt, MD, PhD will give an overview of front-line therapy for adults with Ph+ ALL including how highly-active targeted therapies have improved the prognosis of this disease over the last two decades.
Nicolas Boissel, MD, PhD will discuss current approaches and ongoing clinical trials integrating novel agents for adolescents and young adults with ALL.
Kristen O'Dwyer, MD will provide an update of the treatment of T-cell ALL and future directions in the treatment of this rare disease.
Matthew Wieduwilt, MD, PhD will give an overview of front-line therapy for adults with Ph+ ALL including how highly-active targeted therapies have improved the prognosis of this disease over the last two decades.